BHYHomo sapiens (Human)Cancer cell line

🤖 AI SummaryBased on 10 publications

Quick Overview

Human oral squamous cell carcinoma cell line with known genetic alterations.

Detailed Summary

The BHY cell line is a human oral squamous cell carcinoma cell line derived from a 52-year-old Japanese male. It is characterized by specific genetic mutations, including a nucleotide deletion (G349del) and two point mutations (A478G and T1106C). These mutations result in a truncated p53 protein, which may contribute to its oncogenic potential. BHY cells exhibit distinct proteolytic enzyme expression profiles, with higher levels of MMP-9 and EMMPRIN compared to normal epithelial cells. Additionally, BHY has been used in studies investigating the role of p53 mutations in cancer progression and response to DNA-damaging agents. The cell line is also part of comprehensive genomic and transcriptomic studies, highlighting its utility in understanding cancer biology and therapeutic targets.

Research Applications

Genomic and transcriptomic analysisCancer progression studiesp53 mutation analysisProteolytic enzyme expression profiling

Key Characteristics

Truncated p53 protein due to genetic mutationsAltered proteolytic enzyme expressionUsed in studies of DNA damage response
Generated on 6/16/2025

Basic Information

Database IDCVCL_1086
SpeciesHomo sapiens (Human)
Tissue SourceOral cavity, alveolar ridge[UBERON:UBERON_0004103]

Donor Information

Age52
Age CategoryAdult
SexMale
Raceasian

Disease Information

DiseaseSquamous cell carcinoma of the oral cavity
LineageHead and Neck
SubtypeOral Cavity Squamous Cell Carcinoma
OncoTree CodeOCSC

DepMap Information

Source TypeDSMZ
Source IDACH-000548_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Leu369Pro (c.1106T>C)Unspecified-PubMed=17390010
MutationSimpleTP53p.Met160Val (c.478A>G)Unspecified-PubMed=17390010
MutationSimpleTP53p.Thr118Glnfs*5 (c.351delG) (p.G117fs)Unspecified-PubMed=28683746
MutationUnexplicitPARD3Ex6-15delHomozygous-PubMed=20215515
MutationSimpleCDKN2Ap.Arg58Ter (c.172C>T) (p.Pro72Leu, c.215C>T)Unspecified-PubMed=9598804

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X,Y
CSF1PO
10
D13S317
12,13
D16S539
12
D18S51
14
D19S433
13,14
D21S11
29,31.2
D2S1338
20,24
D3S1358
17
D5S818
10
D7S820
11,12
D8S1179
10
FGA
24
Penta D
13,14
Penta E
14
TH01
9
TPOX
8,11
vWA
15,16
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies.

Zaida M., Delic N.C., Samuels Y., Lyons J.G., Gutkind J.S.

Oncotarget 5:8906-8923(2014).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Characterization of gene expression profiles of 3 different human oral squamous cell carcinoma cell lines with different invasion and metastatic capacities.

Erdem N.F., Carlson E.R., Gerard D.A.

J. Oral Maxillofac. Surg. 66:918-927(2008).

Characterization of 3 oral squamous cell carcinoma cell lines with different invasion and/or metastatic potentials.

Erdem N.F., Carlson E.R., Gerard D.A., Ichiki A.T.

J. Oral Maxillofac. Surg. 65:1725-1733(2007).

Oncogenic mutation of the p53 gene derived from head and neck cancer prevents cells from undergoing apoptosis after DNA damage.

Tachibana M., Imai Y., Fujimori T.

Int. J. Oncol. 30:1089-1097(2007).

Possible contribution of active MMP2 to lymph-node metastasis and secreted cathepsin L to bone invasion of newly established human oral-squamous-cancer cell lines.

Sato M.

Int. J. Cancer 70:120-127(1997).